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Antimicrobial resistance, Ebola, E coli 0157, MERS, SARS, Salmonellosis, 
Zika virus and the critical need for yellow fever vaccines have recently 
emphasized the poignant need for a One Health paradigm shift at all 
levels of academic, corporate, food production, lawmaking, public 
policy, and research systems. oAdditionally, the world must soon feed 
the projected 9 billion people expected to populate its surface with-
out causing further global destruction. Many scientists and One Health 
advocates believe that a One Health approach and application is the 
planet’s ‘Ray of Hope’ for the future because they see as unsustainable 
our current ways of doing business in professional ‘silos’. In addition to 
human, veterinary and environmental health specialists joining hands, 
we need anthropologists, chemists, ecologists, educators, engineers, pri-
vate industry, social scientists, etc. to all work in interactive One Health 
systems and thinking. This will require conjoined concerted effort.
Over the past decade there has been increasing recognition of just 
how much can be learned at the interface of human, animal, environ-
mental and plant domains. From heart transplants to management of 
psychiatric disorders to prosthetic limbs, cancer treatments and vac-
cine development, tremendous knowledge can be gained when we 
create opportunities for trans-professional interactions of researchers 
and clinicians.
This presentation will share a very brief historic context for global 
efforts to resurrect this very old concept, give an update on current 
happenings in the One Health ‘movement’ and give examples of how 
One Health thinking is advancing comparative medicine and transla-
tional research.
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Background: To improve the efficacy of adenoviral (Ad) vector vac-
cines, we have developed an innovative strategy to specifically target 
Ad vector vaccines to DC. To facilitate targeting of the key DC subsets 
responsible for CD8 T cell priming, we have developed a strategy to 
replace the Ad fiber knob with fiber-fibritin chimeras fused to single 
domain antibodies (sdAb) derived from the camelid family. This inno-
vative strategy ablates the native tropism of Ad and permits selective 
and efficient DC targeting based on the specificity of the sdAb. Our 
approach leverages important insights into DC biology that supports 
targeting of CD8α+/CD141+ DC to enhance active immunization.
Materials and methods: Of note, one of the major limits to the use 
of Ad vector vaccines based on human Ad serotype 5 (huAd5) is the 
presence of widespread pre-existing immunity in humans. Simian Ad 
species are closely related but distinct from human Ad. Thus, simian 
Ad offer unique advantages as vaccine vectors including the ability to 
efficiently bypass pre-existing immunity to huAd5, while maintaining 
similar growth properties and genomic structure. To facilitate clinical 
translation of our innovative Ad vector vaccine platform we propose 
to engineer and test DC-targeted gorilla Ad (GAd), as we believe that 
this simian Ad species has the most potential for clinical translation. 
We have establish a research alliance with GenVec, Inc., which will pro-
vide us unique access to novel GAd constructs and reagents to carry 
out this work.
Results: Preliminary data confirms the feasibility and translational 
potential of our innovative Ad vector vaccine platform. We dem-
onstrate here that (1) we can successfully engineer Ad vector vac-
cines targeting DC by replacing the fiber knob domain with chimeric 
fiber-fibritin-sdAb molecules; (2) Ad vector vaccines incorporating 
DC-specific chimeric fiber-fibritin-sdAb are devoid of native adenovi-
rus tropism, and transduce DC with much greater efficiency; (3) DC-
targeted Ad vector vaccines can induce robust immune responses 
in vivo; (4) we can genetically modify GAd in a maner comparative to 
huAd5.
Conclusions: Our DC targeted Ad vaccines will be evaluated in canine 
melanoma patients for indication of anti-tumor immunity. Utility in 
this context will rationalize transition of our targeting modifications 
to the context of GAd to realize a vaccine with direct clinical utility for 
canine and human patents.
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Background: Melanoma is an aggressive disease with 9940 deaths 
expected in 2015. The immune system normally protects against 
development of cancer; however, immune tolerance (a state of anti-
gen unresponsiveness) to melanoma allows progression to a bulky 
or metastatic state. Outbred companion dogs develop malignant 
melanoma (CMM) with similar aggressive metastatic traits. The canine 
immune system both reacts to and is suppressed by similar tumor 
mechanisms as human, unlike other models. Recent clinical studies 
have demonstrated incompletely effective anti-tumor immunotherapy 
efficacy using dendritic cells (DC) vaccines.
Materials and methods: Our goal is to construct a modular immu-
notherapy strategy to stimulate DC to induce potent anti-tumor 
antigen-specific reactions. We will also develop the canine-specific 
immunology toolkit to demonstrate this response. The hypothesis is 
that chimpanzee adenovirus (ChAd) targeted by anti-CD40 camelid 
single-domain antibody (sdAb) containing a human tyrosinase (huTyr) 
cassette (a melanoma xeno-antigen) will cause maturation of mye-
loid DC, elaboration of the xeno-antigen payload, and an anti-tumor 
immune response.
Results: Three client-owned dogs with naturally-occurring CMM 
will be enrolled in a trial of anti-CD40 sdAb-targeted ChAd. Dogs will 
have CMM of Stage I–III disease. Following Ad therapy, anti-melanoma 
immunity will be evaluated using antigen-specific delayed hypersen-
sitivity skin test, immunohistochemistry localization of huTyr on DC in 
skin biopsies, huTyr-specific IgG by ELISA, and ex vivo cytokine elabo-
ration by huTyr stimulation of lymphocytes.
Conclusions: This strategy is expected to generate proof-of-principle 
for viroimmunotherapy in a highly stringent model of disease. The 
immunological confirmation of antigen-specific response will facilitate 
rapid translation to the human clinic.
A4 
Of mice and men (and dogs!): development of a commercially 
licensed xenogeneic DNA vaccine for companion animals 
with malignant melanoma
Philip J. Bergman1,2,3
1Katonah Bedford Veterinary Center, Bedford Hills, NY, 10507, USA; 
2Clinical Studies Division, VCA, Los Angeles, CA 90064, USA; 3Adjunct 
Associate Faculty, Memorial Sloan‑Kettering Cancer Center, New York, NY 
10065, USA
Correspondence: Philip Bergman ‑ Philip.Bergman@vca.com  
Clinical and Translational Medicine 2016, 5(Suppl 1):A4
Melanoma is the most common oral malignancy in the dog. Oral and/
or mucosal melanoma is generally considered an extremely malignant 
tumor with a high degree of local invasiveness and metastatic pro-
pensity. Median survival times for dogs with oral melanoma treated 
with surgery are approximately 12–18, 5–9 and 3 months with stage 
I, II and III disease, respectively. Significant negative prognostic factors 
include stage, size, evidence of metastasis and a variety of histologic 
criteria. Standardized treatments such as surgery, coarse-fractionation 
radiation therapy and chemotherapy have afforded minimal to mod-
est stage-dependent clinical benefits and death is usually due to sys-
temic metastasis. Numerous immunotherapeutic strategies have been 
employed to date with variable clinical efficacy. Xenogeneic DNA 
vaccination with a wide variety of targets induces immune responses 
resulting in generation of Ag-specific T cells and antibodies as well as 
anti-tumor responses and prolongation of survival. These studies led 
to a USDA-CVB multi-site clinical trial of xenogeneic human tyrosinase 
in dogs with stage II or III locally controlled oral malignant melanoma 
with approval in December, 2009. The use of xenogeneic DNA vaccines 
appears to represent a leap forward in clinical efficacy. Oral melanoma 
is a spontaneous syngeneic cancer occurring in outbred, immunocom-
petent dogs and appears to be the most clinically faithful therapeutic 
model for human melanoma; further use of canine melanoma as a 
therapeutic model for human melanoma is strongly encouraged. Our 
results suggest that veterinary and human cancer centers can effec-
tively collaborate and develop therapeutics which lead to governmen-
tal licensure and commercial success.
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Background: Osteosarcoma is an aggressive, mesenchymal bone 
tumor that affects 400 children annually. Standard of care includes 
amputation and chemotherapy however, 30 % of patients die from 
metastatic disease. No therapeutic advances have been made in oste-
osarcoma for 30 years. Pet dogs spontaneously develop osteosarcoma 
that shares similar clinical, biological and molecular features with 
pediatric osteosarcoma. Canine standard of care involves amputation 
and chemotherapy, however, the majority of dogs die from meta-
static disease within 1 year. We have taken a comparative approach to 
determine whether a recombinant HER2 expressing Listeria (Lm-LLO-
chuHER2) can prevent the development of metastatic osteosarcoma.
Materials and methods: 18 dogs that had undergone amputation 
and chemotherapy for HER2  +  appendicular osteosarcoma were 
recruited to a phase 1, 3 + 3 dose escalation clinical trial. After chemo-
therapy, dogs received Lm-LLO-chuHER2 intravenously three times, 
at 3 week intervals. Dogs were evaluated for adverse events, immune 
responses against HER2 and progression free survival and overall 
survival.
Results: Repeat doses of up to 3.3  ×  109 CFU of Lm-LLO-chuHER2 
were well tolerated. 15/18 dogs developed immune responses against 
HER2 within 6  months of immune therapy. Median progression free 
survival was 615 days and overall survival was 965 days compared to 
overall survival of a historical control group that was 420 days.
Conclusions: Administration of Lm-LLO-chuHER2 is safe, induces 
HER2-specific immune responses and prolongs progression free 
and overall survival in dogs with osteosarcoma. These promising 
results pave the way for a clinical trial to determine the effective-
ness of Lm-LLO-chHER2 in preventing metastatic disease in pediatric 
osteosarcoma.
A6 
Human clinical development of ADXS‑HER2
Daniel O’Connor
Advaxis Immunotherapies, Inc., Princeton, NJ 08540, USA
Correspondence: Daniel O’Conner ‑ OConnor@advaxis.com  
Clinical and Translational Medicine 2016, 5(Suppl 1):A6
ADXS-HER2 is an Lm Technology™ immunotherapy product candi-
date being developed by Advaxis to target HER2 expressing cancers. 
ADXS-HER2 has received orphan drug designation by the U.S. Food 
and Drug Administration (FDA) and the European Medicines Agency 
(EMA) for the treatment of osteosarcoma. Advaxis is developing ADXS-
HER2 for both human and animal health, and has seen encouraging 
data in canine osteosarcoma, which is considered a model for human 
osteosarcoma.
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Dr. Nicola Mason, PhD, BVetMed, associate professor of medicine at the 
University of Pennsylvania School of Veterinary Medicine, evaluated 
the immunogenicity, safety, and impact of attenuated, recombinant 
Listeria monocytogenes (Lm) transformed with a HER2/Neu fusion 
protein (ADXS-HER2) on survival in 18 dogs with surgically treated 
osteosarcoma. Advaxis has licensed ADXS-HER2 to Aratana Therapeu-
tics, Inc. for the development of pet therapeutics and expects that the 
HER2 construct will be conditionally approved in 2016 to treat dogs 
with osteosarcoma.
Human epidermal growth factor receptor 2 (HER2) is overexpressed 
in a percentage of solid tumors such as gastric, bladder, brain, pancre-
atic, ovarian and pediatric bone cancer (osteosarcoma). HER2 expres-
sion is associated with more aggressive disease, increased risk of 
relapse and decreased overall survival, and is an important target for 
immunotherapy.
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Naturally-occurring diseases in client-owned dogs and cats often 
mimic diseases that occur in humans. Because pet animals are outbred 
and share their environment with humans, disease in these animals is 
thought to be a better model of human disease than those that can be 
produced in laboratory animals. Therefore, data produced in studies in 
veterinary patients can often promote human development programs. 
This data can also be used as part of the data package submitted to 
regulatory agencies for veterinary products.
Advaxis, Inc. is developing a Listeria monocytogenes-based therapeutic 
vaccine for use in humans with osteosarcoma. Aratana Therapeutics, 
which licensed the product from Advaxis, is developing the same ther-
apeutic vaccine for use in dogs with osteosarcoma, seeking licensure 
for this product from the United States Department of Agriculture, 
Center for Veterinary Biologics (USDA-CVB). Immunotherapies most 
often fall under the jurisdiction of USDA-CVB and the agency requires 
specific information about the manufacturing, safety and effectiveness 
of all products that they govern. Effectiveness data generated to sup-
port human development programs can be used to support the regu-
latory requirements for veterinary use.
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Articular cartilage injuries are a major cause of pain and dysfunction 
in the knee. Translational research in this area led to a number of inno-
vations and the formation of the Mizzou Biojoint Center. This presen-
tation will focus on the innovations and early clinical results from the 
Mizzou Biojoint Center. Several patients have experienced remarkable 
clinical improvement allowing them to resume an active lifestyle.
Several breakthroughs have occurred as a result of the partnership 
between the Missouri Orthopaedic Institute and the Comparative 
Orthopaedics Laboratory at the University of Missouri. We have deter-
mined that at least 70% of the chondrocytes in a transplanted specimen 
must be viable in order to achieve success. We have also analyzed the 
ideal size and shape for grafts that are being transplanted and deter-
mined that a thickness of only 6–7  mm is ideal to balance strength 
with diffusion characteristics. We have also determined that soaking 
the donor graft in the recipients bone marrow aspirate concentrate 
exponentially speeds the process of boney incorporation of the graft. 
Finally, we have determined that storage in a special media at room 
temperature yields grafts with better chondrocyte survival at 60  days 
than chondrocyte survival with conventional storage methods at 
28 days.
Early results of the Biojoint articular cartilage transplants demonstrate 
improvements in function scores, International Knee Documentation 
Committee scores, VAS pain scores, and the promis mobility score. The 
most remarkable improvements occurred at 1 year following the pro-
cedure. Several examples of clinical cases will be discussed.
Biologic replacement of full thickness articular cartilage changes has 
undergone dramatic changes at the Univesity of Missouri as a result of 
a unique translational partnership between the Missouri Orthopaedic 
Institute and the Comparative Orthopaedics Laboratory.
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The Mizzou BioJoint Center is a sub-specialty clinical service dedicated 
to providing cutting edge treatments for joint problems. These treat-
ments are designed to restore patients’ function and quality of life. At 
the center, physicians and scientists work together on a daily basis to 
find optimal, evidence-based solutions for the most common joint dis-
orders affecting society today.
The Mizzou BioJoint Center was birthed from translational research 
performed under the One Health–One Medicine umbrella, which is a 
hallmark focus of research at the University of Missouri. Research in 
the Comparative Orthopaedic Lab that was initially focused on dogs 
and horses proved to be very safe and effective in veterinary medicine 
and so the process of translation to human application was pursued. 
This process involved a team of veterinarians, physicians, and scientists 
working together to develop techniques and instrumentation for pre-
serving and implanting allograft tissues for joint restoration through a 
series of in vitro, ex vivo and animal model studies. This translational 
research came to fruition in terms of validation of pre-clinical safety 
and efficacy based on FDA, ASTM and AATB standards, and was sub-
sequently funded for first-in-man trials. Several of the technologies 
involved in the BioJoint process have been licensed and are now being 
used commercially as well.
Initial results in human patients have been excellent overall and the 
Mizzou BioJoint Center has already become an internationally-rec-
ognized center of excellence for delivering innovative restorative 
solutions for the joint problems experienced by millions of people 
worldwide. Importantly, this concept is still helping veterinary patients 
as well.
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MTF is a registered and certified, non-profit tissue bank that recovers, 
prepares, and distributes allograft tissue forms worldwide for surgical 
use in multiple orthopaedic specialities, wound care, and general and 
plastic reconstructive surgery. MTF provides peer reviewed Founda-
tion Grants and Directed Research Grants to support the advancement 
of allograft science and product development partnerships.
Successful translation of proprietary university research to commer-
cial applications can take many paths. The MIZZOU/MTF partnership 
began with a review of MIZZOU proprietary technology for fresh oste-
ochondral allografts, intellectual property, and in vitro and in vivo data 
provided by MIZZOU. MTF considered the surgeon and patient ben-
efits of the technology, the Regulatory pathway and potential reim-
bursement requirements, synergy of the MIZZOU and MTF goals, and 
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MTF’s competencies to actively support commercial development and 
product distribution in its due diligence review. A partnership was cre-
ated through a Sponsored Research Agreement (SRA) funded by MTF 
that defined the development activity protocols, resources, and safety 
and efficacy outcomes required to translate the technology to com-
mercialization. An Option to License the MIZZOU intellectual property 
including predetermined licensing terms was created simultaneously 
with the SRA.
SRA activity focused on process development and tissue supply by 
MTF and in vitro measurements at MIZZOU. Successful completion of 
the SRA has resulted in initiation of an approved patient assessment 
study and limited distribution of the allograft tissue to select sites 
to create journal publications that will describe the health care and 
patient efficacy benefits of the technology.
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Solving the problems inherent in modern drug discovery will require 
more than just changing how we are going to examine small mol-
ecules and potential targets. It instead will require a completely dif-
ferent mindset that recognizes why drugs fail to come to market, how 
we can utilize data integrated across human and animal health, and 
a precision medicine approach designed to discover new targets and 
lead compounds- possibly before the conditions the target proteins 
underlie are even understood clinically. The advent of clinical whole 
genome sequencing means that the average genetic fitness load car-
ried by individuals—the sum of their proclivity towards disease when 
encountering certain environmental factors- will start to be revealed. 
We analyzed data from publically available sources and carried out 
statistical analysis in R. Our work shows that genes which code for 
the proteins which are the targets of most successful drugs are quite 
evolutionarily conservative- especially when compared to those genes 
which are causal for disease. In addition, orphan diseases in Humans 
have cognates in both companion and farm animals which can be 
studied and developed to help further drug development while at the 
same time expanding the market for new drugs. We conclude that a 
OneHealth approach towards finding new drug targets, and associ-
ated small molecules, is warranted- from both a market perspective 
and an evolutionary one- to maximize successful drug development 
for future precision medicine implementations. We highlight potential 
novel methodologies for finding these targets that will require further 
development.
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contracts to Dr. Wyckoff from NIH 2 R44 GM097902-02A1 
(Dockhorn, PI) and NIH 1 R21 AI113552-01 (Geisbrecht, PI).
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The use of “big data” in healthcare is becoming more widely accepted 
especially with the announcement of the precision medicine initiative. 
The increase in adoption of electronic health records, genomics/pro-
teomics/transcriptomics/etc. databases, and the aggregation of envi-
ronmental data has opened up doors with which researchers can truly 
understand disease transmission and pathogenesis.
Animal health databases tend to be far more robust than even the 
most robust human health databases. The opportunity for the devel-
opment of precision medicine and precision husbandry is wide open, 
but there remains many challenges standing in the way. This presenta-
tion aims to cover the challenges and opportunities that are left in this 
wide open space.
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HealtheIntent is a multi-purpose, programmable platform designed to 
scale at a population level while facilitating health and care at a person 
and provider level. This cloud-based platform enables health care sys-
tems to aggregate, transform and reconcile data across the continuum 
of care. HealtheIntent collects data from multiple, disparate sources in 
near real-time, providing clarity to millions of data points in an action-
able and programmable workflow. It enables organizations to identify, 
score and predict the risks of individual patients, allowing them to 
match the right care programs to the right individuals.
This presentation will focus on the ways in which a platform such as 
this could be used to accelerate the adoption curve of new research 
and connect disparate sources of information to provide a more com-
plete picture of health and wellness for populations. Through integra-
tion of geospatial information, it will be possible to create bridges 
between human and animal health that can be used at the point of 
care. Special attention will be paid to how this will enable further 
research and integration of new knowledge.
Competing interests: Mr. Hays is an employee of Cerner Corporation, 
the provider of the HealtheIntent platform.
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Cancer researchers have a unique opportunity to include naturally 
occurring cancers in pet dogs as translational models in the devel-
opment path of new human cancer drugs, to the ultimate benefit to 
both species. Naturally occurring cancers in pet dogs and humans 
share many features, including histological appearance, tumor genet-
ics, molecular targets, biological behavior, and response to both con-
ventional and novel targeted cancer therapies. Formal integration 
of studies including pet dogs with cancer is becoming a more com-
mon component of an innovative cancer drug development process. 
Because no gold standard treatments exist for pet animals with can-
cer, new treatments can be provided to pet dogs with cancer at ear-
lier stages of progression than human trials. Flexibility in the conduct 
and design of such trials permits serial collection of biologic samples 
and imaging endpoints during exposure to novel cancer agents. 
Lastly, cancer progresses at a faster rate in pet dogs than in humans; 
accordingly, these studies can be completed without interrupting 
the existing development path. The intramural NCI’s Center for Can-
cer Research established the comparative oncology program (COP) 
to develop this novel cancer drug development opportunity, address 
potential risks with this approach, and establish the organizational 
infrastructure to undertake translational clinical trials in pet dogs. This 
clinical trial infrastructure unites study sponsors with 22 academic vet-
erinary centers to support multicenter clinical trials of investigational 
therapeutics. In this presentation we provide examples of such tri-
als and the unique aspects of drug development that are addressed 
within the conduct and design of the trial.
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Many inherited neurodegenerative diseases in our companion ani-
mals share important similarities to human diseases in terms of clinical 
signs, pathology and genetics and may prove to be excellent models 
of these conditions. Veterinary researchers play a critical role in char-
acterization of the natural history of inherited neurologic diseases in 
animals. Recent advances in molecular genetics allow for rapid iden-
tification of the mutation underlying the disease and correlation with 
the genetic basis of the corresponding human disease. Disease muta-
tion discovery enables further understanding of pathophysiologic 
mechanisms and ultimately development of rational approaches to 
therapy. Thus, a naturally-occurring canine disease model offers a ready 
clinical population where therapies can be evaluated in a setting closely 
mimicking human clinical trials.
Therapeutic studies using transgenic rodent models often fail to pre-
dict efficacy and outcome in human patients. As an intermediate-sized 
model of a naturally-occurring neurodegenerative diseases, dogs will 
yield data more relevant to the human disease. Similarities between 
the canine and human nervous systems in size and complexity, and 
the homogeneity in onset and clinical progression of many canine 
diseases facilitate therapy translation. Moreover, utilizing established 
disease measures in canine models provide sensitive and specific 
milestones of disease progression and therapeutic response that par-
allels surrogate markers used in human patients. Importantly, canine 
disease models permit studies of therapy intervention using similar 
procedures as those in human patients. Demonstrating dosing and 
delivery paradigms and safety of therapy in the canine disease models 
will provide key supportive data and improve the probability of clinical 
trial success.
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Duchenne muscular dystrophy (DMD) is caused by dystrophin defi-
ciency. Gene therapy holds a great promise to restore dystrophin 
expression and ameliorate muscle disease. Adeno-associated virus 
(AAV) is currently the leading vector for DMD gene therapy. However, 
AAV can only carry a 5-kb genome while the full-length dystrophin 
coding sequence is 11.2-kb. To overcome this hurdle, investigators 
have developed highly abbreviated synthetic mini- and micro-dystro-
phin genes. The minigenes are 6 to 8-kb in length. They evolve from a 
6.2-kb naturally occurring minigene that results in ambulation to the 
age 61. We have developed a series of dual and tri-AAV vectors that 
can deliver the minigene and even the full-length dystrophin cDNA. 
In dual vectors, the minigene expression cassette is split to two parts 
and individually packaged in an AAV vector. Reconstitution is achieved 
in muscle through engineered recombination signals. Dual AAV mini-
gene delivery has resulted in saturated transduction following direct 
muscle injection and widespread transduction after intravenous injec-
tion in mouse models of DMD. A microgene carries only one-third of 
dystrophin cDNA. We have recently engineered novel microgenes that 
can anchor neuronal nitric oxide synthase (nNOS) to the sarcolemma. 
We further demonstrated therapeutic efficacy in mouse models of 
DMD. In preparation for human translation, we recently tested AAV 
microgene therapy in the canine model. Direct muscle injection ame-
liorated histopathology and improved muscle function. Importantly, a 
single intravenous injection resulted in whole body micro-dystrophin 
expression and amelioration of histological lesions. Our results have 
set the foundation for bodywide gene therapy in DMD patients.
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Autosomal dominant polycystic kidney disease (ADPKD) is a prolifera-
tive disorder in which thousands of cysts develop from renal tubules, 
enlarging over decades of time to eventually overwhelm the kid-
neys. Cyst formation in PKD involves both neoplastic cell growth and 
cyst-filling fluid secretion. Secondary effects of cyst growth including 
inflammatory infiltrates and fibrosis contribute to renal failure. Murine 
genetic models of PKD have been instrumental for mutation analysis, 
structure–function studies, and for elucidating the mechanisms of cyst 
formation, growth and enlargement, and disease progression, and 
have served as models for the development of therapies to slow cyst 
growth and kidney enlargement.
The protein products of the ADPKD genes PKD1 and PKD2 are polycys-
tin-1 and polycystin-2, which are thought to form a membrane-asso-
ciated receptor-channel complex that regulates intracellular calcium. 
Decreasing intracellular calcium can bring about a phenotypic switch 
causing renal epithelial cells to abnormally proliferate in response to 
cyclic AMP agonists. By manipulating cellular calcium or cAMP levels 
it is possible to stimulate cell proliferation and fluid secretion, and in 
mouse and rat models to affect disease severity. Insights derived from 
such studies have led to the development of therapies to decrease 
cAMP and ameliorate cystic disease. One therapy, the vasopressin 
receptor antagonist, tolvaptan, was successfully tested in a phase 3 
clinical trial and is awaiting federal approval. Other therapies based on 
this idea are in the preclinical or clinical trials pipeline.
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Autosomal dominant polycystic kidney disease (ADPKD) is a com-
monly inherited disorder that causes the formation of fluid-filled renal 
cysts leading to renal failure. ADPKD is more common than sickle cell 
anemia and muscular dystrophy combined. Mutations in the gene 
polycystin–1 (PKD1) cause 85 % of ADPKD. The PKD1 gene is very large 
and most families with ADPKD have new mutations in the gene, thus, 
many different mutations cause disease. Feline PKD is also autoso-
mal dominant and has clinical presentations similar to humans. While 
some cats have severe and rapid disease, dying by 4–6  years, many 
cats have less prominent disease and live long lives. PKD affects ~38 
% of Persian cats worldwide, which is approximately 6 % of cats, mak-
ing it the most prominent inherited feline disease. The feline version 
of PKD1 has a mutation that causes a loss of ~25 % of the tail end of 
the protein. The same mutation has not been identified in humans, 
although similar regions of the protein are truncated. Like humans, 
only one copy of the mutation is needed to cause this severe disease 
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and no individuals have two copies of the mutation because it causes 
death of the developing embryo. Only recently, potential effective 
treatments for PKD been discovered. Because the cat’s disease is so 
similar to humans, cats can be used to test the efficacy and longer-
term effects of these new drugs. Therefore, domestic cats can be a valu-
able naturally-occurring model to evaluate treatments and therapies for 
humans with polycystic kidney disease.
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The Polycystic Kidney Disease (PKD) Foundation was founded in 1982 
to promote research into the mechanisms of this most common, 
potentially fatal genetic renal disease, and facilitate the develop-
ment of novel therapeutics to mitigate the progression of PKD and 
its systemic pathophysiological consequences. After the NIH, the PKD 
Foundation is the second largest source of research funds for the two 
forms of PKD, autosomal dominant (ADPKD) and autosomal reces-
sive (ARPKD). ADPKD, which affects approximately 1/500 live births is 
caused by mutations in either the PKD1 or PKD2 genes that code for 
polycystin-1 and polycystin-2, respectively. ARPKD, which is diagnosed 
in about 1/20,000 live births is caused by mutations in PKHD1, which 
codes for fibrocystin. These proteins are associated with the cilium, an 
organelle present in renal tubular cells, as well as many other cell types 
in the body. PKD, therefore, is sometimes referred to as a ciliopathy.
Renal cysts grow inexorably for years or decades, causing the destruc-
tion of adjacent normal kidney parenchyma and in many cases ulti-
mately cause end stage renal disease, which then necessitates renal 
replacement therapy—dialysis or kidney transplant. The PKD Foun-
dation is devoted to finding new therapeutic approaches to slow or 
prevent cyst formation and growth. No specific therapy for PKD is cur-
rently approved in the U.S.
The PKD Foundation currently awards 15 two-year basic and clinical 
research grants and five two-year basic and clinical research fellow-
ships in nephrology every other year to develop novel therapies and 
the next generation of PKD scientists and clinicians.
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Osteoarthritis (OA) is the most common form of arthritis and affected 
about 26.9 million US adults in 2005 at a cost of approximately $60B. 
Based on 2003 NHIS projections, about 67 million (25 %) adults 
aged 18  years or older will have doctor-diagnosed arthritis by the 
year 2030 at a cost that may exceed $220B. OA is also the most com-
mon source of chronic pain in dogs, with 20–50 % of dogs over the 
age of three affected. For this reason, naturally occurring OA in dogs 
should be evaluated for its potential to model human OA. Owing to 
the number of aging baby boomers and OA’s socioeconomic impact, 
it is urgent to improve OA animal models for testing novel therapeu-
tics for translational medicine. Here, we evaluate autologous adipose-
derived stromal vascular fraction, called SVFs. SVF contains beneficial 
cells, cytokines and growth factors and is easily obtained from adults. 
SVF offers a plethora of distinct advantages e.g., rapid isolation, 
autologous sourcing, and simple preparation with no need to expand 
in vitro, large number of cells, wide availability, and is conducive to fast 
clinical deployment.
To test SVF, we conducted an FDA-registered INAD. Design: randomize, 
placebo controlled, double blind clinical study using 22 dogs with OA 
seen at the Kansas State University College of Veterinary Medicine. 
SVF was collected from all patients, and processed using a commer-
cial protocol which has been used in veterinary medicine for >2 years. 
Outcome assessment was done using clinical assessment by blinded 
clinical observer or quality of life and function assessment by the 
blinded owners using previously validated clinical instruments. Quan-
titative outcome assessment was done using pressure sensitive walk-
way. SVF was found to be safe for treating canines with OA. SVF was 
found to improve function with moderate to large standardized effect 
size. This pilot study provided effect size estimates, effectiveness and 
safety endpoints that support a fully powered phase III trial. This works 
supports the contention that naturally occurring OA in a large animal 
model can enable translational medicine.
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Human cells, tissues, and tissue-based products (HCT/Ps) have long 
been regulated by FDA under section 361 of the Public Health Services 
(PHS) Act and 21 CFR Part 1271, using a risk-based approach aimed at 
preventing the introduction, transmission, and spread of communi-
cable diseases. Human tissues are solely regulated under the PHS Act 
provided they meet certain criteria. Two criteria, minimal manipulation 
and homologous use, have been the subject of increased discussion 
and enforcement as the use of HCT/Ps has expanded beyond implan-
tation, transplantation, infusion, or transfer into a human recipient. 
Minimal manipulation is codified as processing that does not alter 
the original relevant characteristics of the tissue. Homologous use is 
codified as repair, reconstruction, replacement, or supplementation 
of a recipient’s cells or tissues with an HCT/P that performs the same 
basic function(s) in the recipient as in the donor. The definitions of 
minimal manipulation and homologous use and their interpretations 
have come under challenge with the recent advances in the use of 
HCT/Ps in regenerative medicine, and have far-reaching consequences 
for current manufacturers of and companies developing HCT/Ps for 
clinical use. If an HCT/P does not meet the criteria set forth in 21 CFR 
1271.10(a), and the establishment that manufactures the HCT/P does 
not qualify for any of the exceptions listed in 21 CFR 1271.15, then 
the HCT/P will be regulated under section 351 of the PHS Act and will 
require premarket clearance or a valid marketing license as a drug, bio-
logic, or medical device.
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Diabetes is a chronic metabolic disorder affecting humans as well as 
several species of domestic animals and pets. In humans, type 1 dia-
betes is a multifactorial autoimmune disease involving progressive 
destruction of pancreatic beta cells ultimately resulting in absolute 
lack of insulin. Type 1 diabetes is treated by injections of exogenous 
insulin, a complicated process requiring elaborate blood glucose mon-
itoring and dosage selection. This has spurred efforts to seek alterna-
tive forms of treatment. Two key approaches now in use or in clinical 
trials include cadaveric islet transplants and use of stem cell derived 
insulin producing beta-like cells capable of correcting the diabetic 
condition. Islet cell replacement therapy is complicated and requires 
intensive patient immunosuppression, often leading to other compli-
cations. Moreover, the paucity of enough cadaveric islets limits this as 
a long term approach to diabetes treatment. Thus, alternative sources 
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of inexhaustible insulin producing cells are needed. Several groups 
have reported success with creating insulin producing cells from 
pluripotent stem cells (embryonic or induced pluripotent stem cells), 
capable of treating diabetes in animal models. These reports have 
facilitated commencement of the first FDA approved clinical trials 
in humans. Among the key challenges for this approach are product 
safety, potency, protection of transplants from the recipient immune 
response requiring encapsulation of transplanted cells, as well as 
determination of appropriate transplant sites that promote effective 
vascularization. Successful resolution of these issues with long term 
independence from insulin injections will pave the way for successful 
treatments for millions of diabetes patients and their family pets.
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Canine diabetes is classified as insulin dependent diabetes mellitus 
similar to type II diabetes in man both characterized by hypoinsu-
linemia, with failure of glycemic control. Peak prevalence in dogs is 
at 7–10  years, females are twice as frequent. Keeshonds, schnauzers 
and terrier breeds are at higher risk. Overall prevalence of 0.5–1.0 %. 
Presentation includes polydipsia, polyuria, polyphagia and weight 
loss. Well tolerated cases can present with cataracts. Persistent fast-
ing hypoglycemia and glycosuria are diagnostic. Commercial insu-
lins, veterinary or human ‘label ‘are typically administered twice a 
day. Dose adjustments are based on urine glucose levels and blood 
glucose via point of care glucometers. Diet and exercise are empha-
sized. Oral hypoglycemic drugs are not utilized as cases present with 
hypoinsulinemia.
Recurrence or persistence of clinical signs is common, suggestive of 
insulin ineffectiveness but is most likely associated with owner compli-
ance/technique. Control in dogs vs. man is characterized as underdo-
ing due to concerns of hypoglycemia. Many owners upon diagnosis 
elect euthanasia because of compliance, or later in the course due to 
the burden of care, hypoglycemia and cataract s/blindness.
There are over 600 scientific publications where dogs were the pre-
clinical model for human islet transplantation, and in greater than 250 
publications, dogs were recipients. Utilizing this scientific base to pro-
vide a therapeutic solution back to dogs is zoobiquitious. Today, novel 
tissue-processing technologies allow for cell-based therapies (CBT) 
without immunosuppression. CBT offers improved glycemic control, 
convenience, and curtails progression of complications (blindness) 
while strengthening the bond on both ends of the leash.
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The emergence of cell-based regenerative therapy has broadened the 
concept of “one medicine” from zoonotic diseases to one of shared 
biology. Diabetes is a disease common to human and companion 
animals. In dogs, the high prevalence, onset, diagnosis and manage-
ment are quite similar to that in the human. Cell-based therapeutic 
approaches include (1) islet transplantation, (2) creation of new islet 
cells to transplant, and (3) mesenchymal stem cell therapy to down-
regulate autoimmunity and stimulate regeneration of beta cells.
The development pathway for human and veterinary products con-
sists of preclinical models, safety and efficacy testing, and manufactur-
ing development. The veterinary FDA regulators (Center for Veterinary 
Medicine) and human regulators (Center for Biologics Evaluation and 
Research) follow generally common pathways to approval of cell 
therapy products. Historically, the dog has been used as a preclinical 
model, but with emergence of clinical veterinary regenerative medi-
cine, in-clinic experiences with naturally-occurring diabetes will ben-
efit the development of new therapies. The regulatory challenges 
include donor sourcing and disease screening, manufacturing meth-
ods development and validation, and clinical testing requirements. 
Each of the three approaches above will require custom designed 
development and regulatory programs.
All mammals share similar stem cell biology and the clinical, experi-
mental, manufacturing learnings should be shared to expedite market 
approval in all species. Veterinary clinical data can be used as more 
realistic predictors of cell therapy outcomes in human clinical studies 
and reduce the cost and time to develop new therapies for dogs and 
humans.
Competing interests: Robert J. Harman is an employee of VetStem 
Biopharma.
